Blue Cross Vermont CEO tells Senate Finance panel changing board makeup would undercut affiliation and stability

Beth Roberts, president and CEO of Blue Cross Vermont, told the Senate Finance Committee on May 13 that a pending proposal to change the carrier’s board composition would undermine an affiliation agreement approved by regulators and could threaten the financial backing her organization relies on.

Roberts said she joined Blue Cross Vermont after a 37‑year career in health insurance and described recent negotiations with UVM Health that she said produced a 12.3% unit‑cost reduction and a new value‑based contract scheduled to take effect Jan. 27. Those steps, she said, show the carrier is pursuing affordability through partnership rather than confrontation.

"We were able to get to agreement on a reduction at UVM of 12.3%," Roberts said, citing the contract negotiated earlier this year. She added the organization has been working to file more affordable products for the market and to respond to recent subsidy changes.

The core of Roberts’s testimony focused on Blue Cross Vermont’s affiliation with Blue Cross of Michigan and the board composition that resulted from that agreement. "When we affiliated with Michigan, that board construct was decided. It is in our affiliation agreement and it was approved by DFR," Roberts told the committee, referring to the state Department of Financial Regulation.

Roberts said the Michigan partnership has provided material support — including a $30 million surplus note the affiliate extended to stabilize Blue Cross Vermont’s finances — and that Michigan leadership provides vendor access and operational expertise the Vermont carrier uses. "They backstopped us with that same type of commitment," she said, describing the Michigan affiliate’s role in stabilizing the carrier after losses in Medicare Advantage products.

She urged lawmakers to consider that changing board membership by statute would alter the affiliation agreement and could damage those supports. "I am not understanding the value that two additional board members would come in and do to an already very strong board," Roberts said. She told senators the board includes a mix of Vermont and Michigan executives who bring financial, clinical and operational experience and that regulators review board minutes, agendas and financials regularly.

Committee members questioned Roberts about regulatory oversight and how board members are selected and removed. Roberts said DFR reviewed submission materials during the affiliation process and continues frequent oversight: "I can't think of something that DFR doesn't see," she said, describing regular information-sharing and reviews of board materials and financial reports. She also described a multi-stage recruitment and onboarding process for board candidates and said the board has not yet had to remove any member for cause.

The chair thanked Roberts for her testimony; the committee did not take a vote but signaled it would continue to consider the board‑composition proposal alongside other regulatory and policy options.

Next steps: Senate Finance indicated it will hold additional review and technical questions before deciding whether to advance any statutory change to Blue Cross Vermont’s board composition.